Riordan Lewis & Haden | Equity Partners Acquires Nutritional Therapy Provider DCRX Infusion
LOS ANGELES, Aug. 3, 2012 /PRNewswire/ — Riordan Lewis & Haden | Equity Partners (RLH) is pleased to announce its acquisition of DCRX Infusion, a leading provider of customized nutritional therapy to patients with end stage renal disease. DCRX, based in Sunrise, Florida, provides products and services to dialysis centers on a nationwide basis.
RLH is privileged to partner in this investment with Robert Funari, an experienced healthcare executive with a successful background in building specialty pharmaceutical companies. Prior to partnering with RLH, Bob was CEO of Crescent Healthcare and of Syncor International.
According to Michel Glouchevitch, a partner at Riordan Lewis & Haden, “In today’s rapidly changing healthcare environment, DCRX is well positioned to continue to achieve significant growth because the Company provides cost-effective clinical care and outstanding service. With the benefit of Bob Funari’s leadership and expertise, DCRX will accelerate its success and improve the quality of life for more dialysis patients.”
Robert Funari, CEO of DCRX Infusion added, “I look forward to working with the excellent DCRX team. Their passion to help dialysis patients, combined with the strategic insight that RLH brings from its 30 year history of helping build high performance service enterprises, are the building blocks which excite me about this outstanding growth opportunity.”
DCRX assists dialysis patients who are at higher risk of adverse clinical outcomes because of chronic malnutrition. The Company’s skilled clinicians work with referring nephrologists to formulate and deliver the appropriate parenteral nutrition therapy for each patient. DCRX also provides a team of pharmacists, nurses, and dieticians that offer comprehensive clinical consulting support for dialysis centers and their patients. Through this combination of customization and responsive service, the Company has achieved exceptional growth.
Skyline Global Partners, a Chicago-based private equity firm, also participated in the DCRX Infusion investment.
Riordan, Lewis & Haden is a leading private equity firm based in Southern California which invests in high growth, lower middle market, enterprises. Focused on business services, healthcare, and government services, RLH has a demonstrated track record of consistent success over the past 30 years. RLH provides capital and assists portfolio company management teams as they navigate the opportunities and challenges of rapid growth. The firm currently manages over $600 million of assets and is actively seeking new portfolio companies.
For more information please contact:
Riordan Lewis & Haden | Equity Partners
Visit us online:
SOURCE Riordan Lewis & Haden | Equity Partners